For other common markers of CSCs, such as CD90 and ALDH that could be theoretically ideal targets for CAR‐T therapy, unfortunately, there is no reported studies using CD90 or ALDH‐specific CAR‐T cell for cancer treatment. Here, THY1 is linked to cancer.